Author: admin

Voyage Management Software Market Valued at USD 2.13 Billion in 2024, Forecasted for Robust Growth

“With a market size of USD 2.13 billion in 2024, the Voyage Management Software Market is expanding rapidly, fueled by technological advancements in shipping logistics, route optimization, and real-time fleet tracking solutions.”
The Voyage Management Software Market is anticipated to expand from USD 2.29 billion in 2025 to USD 4.33 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.32% throughout the forecast period (2025–2034). Furthermore, the market size for Voyage Management Software was estimated at USD 2.13 billion in 2024.

The voyage management software market is experiencing significant growth, driven by the increasing demand for efficient maritime operations, real-time data analytics, and enhanced fleet management. Voyage management software provides comprehensive solutions for planning, tracking, and optimizing vessel routes, ensuring improved fuel efficiency and regulatory compliance. The maritime industry is undergoing rapid digital transformation, with stakeholders seeking solutions that reduce operational costs and enhance sustainability. The integration of artificial intelligence, machine learning, and big data analytics into voyage management software has revolutionized the sector, allowing shipping companies to make data-driven decisions and improve overall performance. The market is also being influenced by stringent environmental regulations that require shipping companies to adopt more efficient navigation systems to reduce carbon emissions. As globalization drives international trade, the demand for effective voyage management software continues to rise, with major shipping lines, cargo carriers, and logistics providers investing in advanced digital solutions to streamline their operations.

Get An Exclusive Sample of the Research Report at: https://www.marketresearchfuture.com/sample_request/24842

Market SegmentationThe voyage management software market can be segmented based on component, deployment mode, application, and end-user. By component, the market is divided into software solutions and services, with software solutions holding a significant share due to increasing automation in maritime operations. Deployment mode is categorized into cloud-based and on-premises solutions, with cloud-based platforms witnessing higher adoption due to their scalability, accessibility, and cost-effectiveness. In terms of application, the market includes fleet management, route optimization, fuel management, regulatory compliance, and performance monitoring. Fleet management and route optimization are key applications as shipping companies seek to enhance operational efficiency and reduce costs. The end-user segment comprises shipping companies, logistics providers, port authorities, and government agencies, with shipping companies accounting for the largest share due to their direct involvement in vessel management and voyage planning.

Market Key PlayersThe voyage management software market features several prominent players that offer advanced solutions for maritime operations. Companies such as:

  • Cargotec
  • Chevron
  • Wartsila
  • ExxonMobil
  • Marine Software Solutions
  • MacGregor
  • Wilhelmsen
  • GEA
  • Shell
  • Transas
  • Yara Marine Technologies
  • BP
  • Alfa Laval
  • OrbitMI Technologies
  • Veson Nautical
  • SeaRates

Buy this Premium Research Report | Immediate Delivery Available at – https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=24842

Market OpportunitiesThe growing emphasis on sustainable shipping practices presents a significant opportunity for the voyage management software market. As the shipping industry faces increasing pressure to reduce carbon emissions, voyage optimization software can play a crucial role in achieving sustainability goals. The adoption of AI-powered predictive analytics is another major opportunity, enabling real-time monitoring of vessel performance, fuel consumption, and maintenance requirements. The integration of blockchain technology in voyage management software is also gaining traction, enhancing transparency, security, and data integrity in maritime operations. Additionally, the expansion of global trade and the rise of e-commerce have increased the demand for efficient logistics and supply chain solutions, driving the adoption of advanced voyage management software. Emerging economies in Asia-Pacific and Latin America present untapped growth opportunities, with governments and private enterprises investing in maritime infrastructure and digital transformation.

Regional AnalysisThe voyage management software market exhibits regional variations, with North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa being key geographical segments. North America leads the market due to the presence of major shipping companies, advanced maritime infrastructure, and high adoption of digital solutions. Europe follows closely, driven by stringent environmental regulations and a strong emphasis on sustainable shipping practices. The Asia-Pacific region is expected to witness the highest growth rate, attributed to the rapid expansion of international trade, increasing maritime activities, and government initiatives to modernize ports and shipping operations. China, Japan, and South Korea are major contributors to the market in this region, with strong investments in smart shipping technologies. Latin America and the Middle East & Africa are also emerging markets, with growing maritime trade and infrastructure development fostering demand for advanced voyage management solutions.

Recent DevelopmentsThe voyage management software market is witnessing continuous advancements and strategic collaborations. Companies are integrating AI, machine learning, and big data analytics to enhance predictive maintenance and optimize voyage planning. In recent years, Wärtsilä launched its Smart Marine Ecosystem, focusing on digital transformation and automation in the maritime sector. Kongsberg Gruppen introduced advanced navigation systems equipped with AI-driven analytics for real-time decision-making. ABB Ltd has expanded its digital maritime solutions with new fuel efficiency modules, helping shipping companies comply with environmental regulations. SAP SE has enhanced its logistics and supply chain integration capabilities, enabling seamless data sharing across stakeholders. The adoption of blockchain technology is also gaining traction, with several industry players exploring its potential to improve transparency and reduce fraud in maritime operations. As digitalization accelerates, the voyage management software market is set to experience substantial growth, driven by innovation, regulatory compliance, and the increasing demand for efficient maritime operations.

Top Trending Reports:

Augmented Reality Glas Market: https://www.marketresearchfuture.com/reports/augmented-reality-glas-market-26402

Cloud Logistic Market: https://www.marketresearchfuture.com/reports/cloud-logistic-market-26413

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Voyage Management Software Market Valued at USD 2.13 Billion in 2024, Forecasted for Robust Growth

Dyspnea Market Expected to rise, 2032 | United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Relief Therapeutics, AstraZeneca, GlaxoSmithKline, Novartis AG, Boehringer Ingelheim

“Dyspnea Market Expected to rise 2032, DelveInsight”
The Dyspnea market growth is driven by factors like increase in the prevalence of Dyspnea, investments in research and development, entry of emerging therapies during the study period 2020-2032.

The Dyspnea market report also offers comprehensive insights into the Dyspnea market size, share, Dyspnea epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dyspnea market size growth forward.

Some of the key highlights from the Dyspnea Market Insights Report:

  • Several key pharmaceutical companies, including United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Relief Therapeutics, AstraZeneca, GlaxoSmithKline, Novartis AG, Boehringer Ingelheim, and others, are developing novel products to improve the Dyspnea treatment outlook.

  • In October 2024, the FDA approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by eosinophilic inflammation. This marks the first biologic therapy approved for COPD in the U.S., aiming to reduce exacerbations and improve lung function. ​

  • Approved by the FDA in June 2024, Ohtuvayre is an inhaled maintenance therapy for adults with COPD. As a first-in-class dual inhibitor of phosphodiesterase 3 and 4, it offers both bronchodilator and anti-inflammatory effects, enhancing lung function and reducing symptom exacerbations. ​

  • In March 2024, the FDA approved sotatercept for treating PAH in adults. This novel therapy improves exercise capacity and reduces the risk of clinical worsening events by targeting activin signaling pathways, offering a new approach to managing PAH-related dyspnea. ​

  • In August 2024, the FDA granted Breakthrough Therapy Designation to Tezspire as an add-on maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype. This designation facilitates the development and review of therapies that may offer substantial improvements over existing treatments. ​

  • As per DelveInsight analysis, the Dyspnea market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Dyspnea Market Landscape

Dyspnea Overview

Dyspnea is the medical term for shortness of breath or difficulty breathing. It can feel like a tightness in the chest, a sensation of suffocation, or an increased effort to breathe.

Do you know the treatment paradigms for different countries? Download our Dyspnea Market Sample Report

Dyspnea Epidemiology Insights

  • Dyspnea is notably prevalent among oncology patients, particularly those with advanced stages of cancer.

Dyspnea Epidemiology Segmentation

DelveInsight’s Dyspnea market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dyspnea historical patient pools and forecasted Dyspnea patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dyspnea Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

  • Dyspnea Prevalence

  • Age-Specific Dyspnea Prevalence

  • Gender-Specific Dyspnea Prevalence

  • Diagnosed and Treatable Cases of Dyspnea

Visit for more @ Dyspnea Epidemiological Insights

Dyspnea Market Outlook

​The global dyspnea treatment market is experiencing significant growth, driven by the increasing prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and pneumonia.

Key Factors Driving Dyspnea Market Growth:

  • Rising Respiratory Disorders: The increasing incidence of conditions like COPD and asthma contributes significantly to the demand for dyspnea treatments. ​

  • Air Pollution: Elevated pollution levels exacerbate respiratory issues, leading to a higher prevalence of dyspnea. ​

  • Aging Population: An older demographic is more susceptible to respiratory ailments, thereby increasing the need for effective dyspnea management.

The dyspnea treatment market is poised for substantial growth in the coming years, driven by factors such as the rising prevalence of respiratory disorders, environmental challenges, and demographic shifts. Ongoing advancements in treatment modalities and increased healthcare investments are expected to further propel market expansion.

Dyspnea Key Companies

  • United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Relief Therapeutics, AstraZeneca, GlaxoSmithKline, Novartis AG, Boehringer Ingelheim, and others

For more information, visit Dyspnea Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Dyspnea Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Dyspnea, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Dyspnea epidemiology in the 7MM

  • Dyspnea marketed and emerging therapies

  • Dyspnea companies

  • Dyspnea market drivers and barriers

Table of Contents:

1 Dyspnea Market Key Comprehensive Insights

2 Dyspnea Market Report Introduction

3 Competitive Intelligence Analysis for Dyspnea

4 Dyspnea Market Analysis Overview at a Glance

5 Executive Summary of Dyspnea

6 Dyspnea Epidemiology and Market Methodology

7 Dyspnea Epidemiology and Patient Population

8 Dyspnea Patient Journey

9 Dyspnea Treatment Algorithm, Dyspnea Current Treatment, and Medical Practices

10 Key Endpoints in Dyspnea Clinical Trials

11 Dyspnea Marketed Therapies

12 Dyspnea Emerging Therapies

13 Dyspnea: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Dyspnea

16 Dyspnea Market Key Opinion Leaders Reviews

18 Dyspnea Market Drivers

19 Dyspnea Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Dyspnea Epidemiology 2032

DelveInsight’s “Dyspnea – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Dyspnea epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dyspnea Pipeline 2024

“Dyspnea Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dyspnea market. A detailed picture of the Dyspnea pipeline landscape is provided, which includes the disease overview and Dyspnea treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dyspnea Market Expected to rise, 2032 | United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Relief Therapeutics, AstraZeneca, GlaxoSmithKline, Novartis AG, Boehringer Ingelheim

New Jersey Small Businesses Enhance Payroll Processing Process to Meet Evolving Compliance Requirements

“payroll processing process in New Jersey”
Small businesses in New Jersey are optimizing their payroll processing process to meet evolving tax laws and compliance requirements. With growing complexities in payroll management, companies are turning to streamlined solutions to avoid costly errors, ensure timely filings, and enhance operational efficiency. Expert-led payroll services help businesses simplify payroll operations while staying compliant.

Miami, Florida, March 03, 2025 – New Jersey’s small businesses and startups are enhancing their payroll processing process to stay ahead of evolving tax laws and compliance requirements. As businesses face increasing pressure to meet regulatory mandates and ensure accurate salary processing, many owners are turning to streamlined solutions to avoid costly errors and penalties. With the growing complexity of payroll management, businesses are adopting smarter payroll processing process in New Jersey to reduce operational disruptions and ensure seamless tax calculations, timely filings, and employee classifications. This proactive approach helps businesses navigate challenges while supporting growth and financial stability.

Payroll Processing Process in New Jersey involves more than salary distribution. Employers must handle tax withholdings, comply with wage laws, manage benefits deductions, and meet strict federal and state tax deadlines. For startups lacking dedicated payroll personnel, these responsibilities can become overwhelming, increasing the risk of costly errors and missed deadlines. Compliance with New Jersey’s labor laws—including minimum wage updates, paid leave policies, and overtime regulations—requires expert knowledge that many small businesses may not have.

“New Jersey businesses need a payroll system that minimizes errors, ensures compliance, and streamline operations,” said Ajay Mehta, CEO of IBN Technologies. “By outsourcing payroll, small businesses can focus on growth while eliminating the stress of tax filings, wage calculations, and compliance monitoring.”

Managing the payroll processing process in New Jersey demands careful attention to employee classifications, tax deductions, and year-end reporting. Errors in Social Security, Medicare, or unemployment insurance contributions can lead to legal consequences. Additionally, businesses that engage independent contractors must ensure accurate classification to avoid regulatory scrutiny. For many startups, these complex payroll requirements make outsourcing a practical and cost-effective solution.

IBN Technologies simplifies payroll management with cloud-based transformation that reduces manual errors while ensuring full compliance with state and federal laws. The company’s payroll services include direct deposit processing, advanced tax filings, preparation of employee tax documents, benefits administration, and secure payroll data management. By seamlessly integrating with existing accounting systems, IBN Technologies enables businesses to optimize payroll operations without disruptions.

Book Your Free Consultation! Get personalized financial solutions—Book Now-

https://www.ibntech.com/free-consultation/?pr=ABnewswire

“Payroll compliance is critical for business stability,” added Mehta. “By leveraging automation and expert-led payroll services, small businesses can reduce financial risks and enhance operational efficiency.”

Security is another key factor in the payroll processing process in New Jersey. Handling sensitive employee data requires stringent security measures to prevent fraud and unauthorized access. IBN Technologies employs advanced encryption and cloud-based security protocols to ensure that payroll data always remains protected.

Custom Plans for Every Business! Find a bookkeeping package that fits your budget now- https://www.ibntech.com/pricing/?pr=ABnewswire

For small businesses and startups an efficient payroll processing process in New Jersey is essential for financial growth and operational stability. Partnering with IBN Technologies allows business owners to streamline payroll operations, improve compliance, and gain peace of mind knowing their payroll is managed by industry professionals. With a focus on accuracy, security, and regulatory compliance, IBN Technologies empowers businesses to navigate payroll complexities effortlessly, allowing them to concentrate on expansion and long-term success.

Related services:                     

Tax Preparation and Support            

https://ibntech.com/us-uk-tax-preparation-services/?pr=ABnewswire

About IBN Technologies                            

IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive efficiency and growth.

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Jersey Small Businesses Enhance Payroll Processing Process to Meet Evolving Compliance Requirements

Aquafeed Market Expansion: Trends, Growth Drivers, Opportunities, Top Companies, and Future Outlook

“MarketsandMarkets™”
Aquafeed Market Size, Share, and Growth Trends Report by Ingredient (Soybean, Corn, Fishmeal, Fish Oil, Additives), Species (Fish, Crustaceans, Mollusks), Function (Nutrition, Growth Promoters, Immunity, Texture & Palatability), Lifecycle, Form and Region – Global Industry Forecast to 2029

The global aquafeed market is on a trajectory of significant expansion, with an estimated value projected to reach USD 84.19 billion by 2029 from the 2024 valuation of USD 58.92 billion, displaying a promising Compound Annual Growth Rate (CAGR) of 7.4%. Demand for seafood and innovation in aquaculture technologies are driving the growth of the aquafeed market. According to FAO, global aquaculture production in 2022 reached a record level of 130.9 million tonnes, which represents 51% of global fish production. This surge in aquaculture has resulted in demand for high-quality aquafeed to ensure optimum growth and health in farmed species of aquatic origin.

Aquafeed Market

According to NMFS, US aquaculture production reached more than 660 million pounds of seafood in 2022 alone; this level of production was backed by the aquafeed market. According to the USDA, there has been a steady increase in aquafeed production, driven by rising domestic aquaculture practices and specialized feed formulations.

Aquafeed Market Drivers: Increase in usage of functional aquafeed additives

The key reason behind the growing use of functional aquafeed additives is the increasing prevalence of aquatic diseases, which pose serious threats to fish and shrimp farming industries. Rising water temperatures further exacerbate the issue by creating favorable conditions for the rapid spread of infectious fish diseases. A study by NCBI (National Center for Biotechnology Information) published in October 2024, analyzing 104 papers from 2003 to 2022 found that 54% of the research focused on parasites, especially proliferative kidney disease, with 22% examining bacterial infections in fishes. Most studies emphasized freshwater species and farmed fish, showing that increased temperatures, along with factors like pH and salinity changes, pose major threats to fish health and global aquaculture.

This surge in disease prevalence is a key driver behind the growing use of functional aquafeed additives. Probiotics, prebiotics, and immune-boosting compounds are being increasingly integrated into aquafeeds to combat these health risks. Functional additives help improve gut health, enhance immunity, and reduce disease outbreaks, offering a sustainable solution to the challenges posed by climate change and its effects on fish. Therefore, addressing aquatic pathogens through improved management and the use of functional additives has become more essential.

Aquafeed Market Opportunities: Growth in support from governments

The growing support from governments worldwide presents significant opportunities for the aquafeed market, especially as global demand for seafood is projected to increase by 70% over the next 30 years (source: USDA). With capture fisheries’ harvests either stable or declining, the need for a rapid expansion in aquaculture has become increasingly evident. Governments are recognizing this and have ramped up efforts to ensure the sustainable growth of the aquaculture industry, offering a range of funding and support initiatives that create a conducive environment for innovation and growth in aquafeed production.

In the United States, the National Institute of Food and Agriculture (NIFA) plays a crucial role in driving research, technology development, and Extension programs related to aquaculture. For example, NIFA’s efforts in supporting innovations to enhance feed formulations, disease prevention, and sustainable aquaculture practices are directly contributing to better-aquafeed products. By investing in aquaculture research that improves feed efficiency and sustainability, government initiatives create significant opportunities for the development of functional additives, alternative feed sources, and environmentally friendly ingredients in aquafeeds. These advancements are crucial for responding to the challenges of increased global seafood demand and reduced availability of traditional feed ingredients.

Dry form accounted for higher market share among form segments in 2023.

In the aquafeed market, the dry form includes pellets, crumbles, and powders. Dry feeds are mainly predominant due to the facility and convenience they provide over the other forms. Dry aquafeeds are easier to store, handle, and move compared to wet and liquid feeds that need more delicate management to avoid spoilage or contamination. This particularly fits large-scale aquaculture operations where logistic efficiency is very important.

Dry feeds in pellet form are favored by many aqua culturists as they offer a stable and precisely formulated nutritional profile. These feeds are designed to meet the specific dietary needs of various aquatic species, ensuring they receive balanced nutrition for optimal growth. Companies like ADM(US) and Cargill Incorporated (US) produce pelletized feeds for species such as salmon and shrimp, carefully blending proteins, fats, vitamins, and minerals in exact proportions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1151

Grower feed in lifecycle segment to be dominant market during forecast period.

Grower aquafeed meets the demand of aquatic species, switching to a more developed growth stage, normally containing 30–40% protein, which supports the continuity of development but synchronizes growth at reduced rates. It is cost-effective as it provides a balanced nutritional formulation tailored for optimal fish growth. Its pelletized form improves feed efficiency, reducing waste and enhancing nutrient absorption. This results in better growth and lower feed costs, making it economical for large-scale aquaculture operations. Grower feed, mostly in pelletized form, improves feed utilization and reduces waste due to the advanced feeding skills of the fish. Better feed conversion and lower waste combine with increased efficiency to help trigger growth. Technological advancements have led to grower feeds being refined with additives such as probiotics and prebiotics, enhancing performance and ensuring animal health. This has further cemented the importance of this stage in the industry. The dominance of grower feeds in the aquafeed lifecycle stage stems from their increasing ability to meet the nutritional requirements of fish, thus contributing to the sustainability and efficiency of the aquaculture industry.

Asia Pacific is the fastest growing region in the aquafeed market.

According to the FAO, in 2022, Asia produced 119.7 million tons of aquaculture, representing 91.4% of the global production. China led with 40%, followed by Indonesia with 10% and India with 7%. This significant output underscores Asia’s dominance in global aquaculture. This intensive production is directly related to the high demand for seafood, which has resulted from a large, growing population and rising per-capita incomes. According to the National Bureau of Statistics of China in 2023, the country is the largest producer and consumer of seafood globally; it consumes approximately 63.4 million metric tons annually. Producers are compelled to expand and enhance their offerings to meet the nutritional needs of aquaculture farms. Government policies in the region further back this growth. The 14th Five-Year Plan of China focuses on both sustainable aquaculture and technological innovation, thereby improving production efficiency. Similarly, the Indian National Fisheries Policy is targeted at expansion in aquaculture and infrastructure investments, thus stimulating growth in the market.

Top 10 Companies in the Aquafeed Market

Cargill, Incorporated (US)

dsm-firmenich (Switzerland)

Nutreco (Netherlands)

Alltech (US)

Purina Animal Nutrition LLC (US)

Adisseo (France)

Aller Aqua Group (Denmark)

BioMar Group (Denmark)

Recent Developments of Aquafeed industry

In December 2024, Aller Aqua Group partnered with AquaRech to improve access to high-quality fish feeds for fish farmers across Kenya. This collaboration combines Aller Aqua’s expertise in premium feed production with AquaRech’s extensive Last Mile Distribution System, ensuring consistent supply and accessibility in key regions. The partnership is set to enhance fish health and growth, significantly reducing production cycles from 14 to 8 months, while supporting sustainable aquaculture practices. This strengthens Aller Aqua’s position as one of the leaders in the African aquaculture industry, driving growth and supporting local farming communities.

In June 2024, Nutreco launched its innovative “Garden of the Future,” marking a significant advancement in phytotechnology. This groundbreaking initiative focuses on developing cutting-edge phytotechnology solutions designed to enhance the performance, health, and welfare of aquatic species, as well as farm and companion animals. The “Garden of the Future” represents a forward-thinking approach, leveraging advanced plant-based technologies to improve animal nutrition and overall well-being.

In January 2024, the joint venture between ADM and Vitafort opened a new state-of-the-art feed mill in Hungary that is poised to achieve full production capacity. This reflects ADM’s steadfast commitment to ushering in a new era of modernization in the region’s production infrastructure.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1151

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

 

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/aquafeeds-market-1151.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aquafeed Market Expansion: Trends, Growth Drivers, Opportunities, Top Companies, and Future Outlook

AI in Asset Management Market Poised to Reach USD 920.51 Billion, Expanding at a 26.92% CAGR by 2034

“” AI in Asset Management Market: A financial analyst using AI-driven dashboards with predictive analytics, stock market trends, and automated investment insights “”
AI in asset management market is revolutionizing financial services by leveraging machine learning and predictive analytics to optimize investment strategies and risk management.

Market Overview:

According to a new report published by Market Research Future (MRFR), AI in Asset Management Market is expected to expand from USD 107.69 billion in 2025 to USD 920.51 billion by 2034, reflecting a CAGR of 26.92% over the forecast period (2025–2034). Furthermore, the market was valued at USD 84.85 billion in 2024.

The integration of Artificial Intelligence (AI) into the asset management sector has revolutionized traditional investment strategies, offering enhanced data analysis, improved decision-making, and operational efficiency. This transformation is driven by the need to process vast amounts of data swiftly and accurately, enabling asset managers to respond to market dynamics with unprecedented agility.

AI technologies facilitate portfolio optimization, risk assessment, and predictive analytics, thereby enhancing the overall efficiency and effectiveness of asset management operations.

Download Sample Report (Get Full Insights in PDF – 128 Pages) at –https://www.marketresearchfuture.com/sample_request/26543

Key Companies in the AI in Asset Management Market Include:

  • State Street Corporation
  • BlackRock
  • Schroders
  • Franklin Templeton Investments
  • P. Morgan Asset Management
  • Allianz Global Investors
  • Rowe Price
  • Invesco
  • Amundi Asset Management
  • Vanguard
  • Fidelity Investments
  • UBS Asset Management
  • Morgan Stanley Investment Management
  • Goldman Sachs Asset Management
  • Northern Trust Asset Management

 

Several prominent organizations are leading the integration of AI into asset management. Companies such as BlackRock, Vanguard, and State Street have incorporated AI-driven tools to optimize portfolio management and enhance client services. Technology giants like IBM and Microsoft provide AI solutions tailored for financial services, enabling asset managers to leverage machine learning and natural language processing for data analysis and decision support. Additionally, fintech firms like Numerai and Kensho are introducing innovative AI applications, offering predictive modeling and analytics that challenge traditional asset management paradigms.

Market Segmentation:

The AI in asset management market can be segmented based on technology, deployment mode, application, and industry vertical.

By Technology: This includes machine learning, natural language processing (NLP), predictive analytics, and other emerging AI technologies.

By Deployment Mode: Solutions are offered either on-premises or via cloud-based platforms, with cloud adoption increasing due to its scalability and cost-effectiveness.

By Application: Key applications encompass portfolio optimization, risk and compliance management, process automation, conversational platforms, and data analysis.

By Industry Vertical: While the primary focus is on banking, financial services, and insurance (BFSI), other sectors such as healthcare, retail, e-commerce, media and entertainment, energy and utilities, and automotive are also exploring AI-driven asset management solutions.

Market Dynamics:

The rapid adoption of AI in asset management is influenced by several factors:

Data-Driven Decision Making: AI enables the analysis of large datasets to identify patterns and trends, facilitating informed investment decisions.

Operational Efficiency: Automation of routine tasks through AI reduces operational costs and minimizes human errors.

Regulatory Compliance: AI assists in monitoring compliance with evolving regulations, ensuring that asset management practices adhere to legal standards.

Client Personalization: AI-driven insights allow for the customization of investment strategies to meet individual client preferences and risk profiles.

However, challenges persist, including concerns about data privacy, the need for significant initial investments, and the requirement for skilled personnel to manage AI systems. Moreover, ensuring the transparency and interpretability of AI models remains a critical issue to build trust among stakeholders.

Recent Developments:

The AI in asset management landscape is continually evolving, marked by notable developments:

Mergers and Acquisitions: Asset managers are engaging in strategic partnerships and acquisitions to enhance their AI capabilities. For instance, Amundi’s acquisition of wealth software firm Aixigo for €149 million exemplifies efforts to integrate advanced AI solutions into traditional asset management frameworks.

AI-Powered Financial Advisory Services: Platforms like Robinhood have announced plans to introduce AI-driven financial advice, aiming to provide cost-efficient support for portfolio management, tax planning, and retirement strategies. This initiative reflects a broader trend of democratizing access to sophisticated investment tools through AI.

AI-Focused Investment Funds: The launch of AI-centric exchange-traded funds (ETFs) has gained momentum, with over one-third of AI-themed ETFs introduced in 2024 alone, collectively managing assets worth $4.5 billion. This trend indicates growing investor interest in AI-driven investment opportunities.

Browse In-depth Market Research Report –https://www.marketresearchfuture.com/reports/ai-in-asset-management-market-26543

Regional Analysis:

Geographically, the adoption of AI in asset management varies:

North America: Leading the market with a significant share, North America’s dominance is attributed to advanced technological infrastructure, substantial investments in AI research, and the presence of major financial institutions. The region accounted for over 50% of the global AI in asset management market revenue in 2022.

Europe: European asset managers are increasingly integrating AI to enhance investment strategies and operational efficiency. The region’s regulatory environment supports innovation, and there is a strong emphasis on ethical AI deployment.

Asia-Pacific: This region is experiencing rapid growth in AI adoption within asset management, driven by technological advancements and a burgeoning fintech ecosystem. Countries like China, Japan, and India are at the forefront, leveraging AI for enhanced financial services. Asia-Pacific is anticipated to showcase significant growth with the fastest CAGR in the upcoming period.

Explore MRFR’s Related Ongoing Coverage In ICT Domain:

Panel Level Packaging Market –https://www.marketresearchfuture.com/reports/panel-level-packaging-market-43045

Passive Optical Network Pon Equipment Market –https://www.marketresearchfuture.com/reports/passive-optical-network-equipment-market-43004

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AI in Asset Management Market Poised to Reach USD 920.51 Billion, Expanding at a 26.92% CAGR by 2034

Emphysema Market Expected to rise, 2032 | Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, expected to drive market

“Emphysema Market Expected to rise 2032, DelveInsight”
The Emphysema market growth is driven by factors like increase in the prevalence of Emphysema, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Emphysema market report also offers comprehensive insights into the Emphysema market size, share, Emphysema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Emphysema market size growth forward.

Some of the key highlights from the Emphysema Market Insights Report:

  • In early 2024, the FDA expanded the use of Dupixent, developed by Regeneron Pharmaceuticals and Sanofi, to include chronic obstructive pulmonary disease (COPD), which encompasses emphysema. This marks the first targeted biological therapy approved for COPD. Clinical trials demonstrated that Dupixent reduced moderate-to-severe exacerbations by 30% over 52 weeks and improved lung function, with a favorable safety profile. ​

  • In June 2024, Verona Pharma’s Ohtuvayre received FDA approval as the first inhaled therapy with a novel mechanism of action for COPD in over two decades. Ohtuvayre is a dual inhibitor of the phosphodiesterase 3 and 4 enzymes, offering both bronchodilation and anti-inflammatory effects. Phase 3 trials showed significant improvements in lung function and a 40% reduction in exacerbations over 24 weeks in patients with moderate to severe COPD. ​

  • Olympus Corporation expanded the availability of its Spiration Valve System in March 2022. This minimally invasive device reduces lung hyperinflation in emphysema patients, leading to improved breathing and quality of life. ​

  • According to DelveInsight, the Emphysema Market is projected to grow at a strong rate from 2023 to 2032, driven by the introduction of new therapies and an increasing number of cases.

  • Several leading pharmaceutical and biotechnology companies, including Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Pfizer, Mylan, and Novartis, are actively engaged in advancing treatments for emphysema.

  • As per DelveInsight analysis, the Emphysema market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Emphysema Market Landscape

Emphysema Overview

Emphysema is a chronic lung disease that falls under chronic obstructive pulmonary disease (COPD). It causes damage to the air sacs (alveoli) in the lungs, making it difficult to breathe. Over time, the walls of the alveoli weaken and rupture, reducing the surface area available for oxygen exchange. This leads to shortness of breath, coughing, and wheezing.

Do you know the treatment paradigms for different countries? Download our Emphysema Market Sample Report

Emphysema Epidemiology Insights

  • Emphysema is a chronic lung condition characterized by the destruction of alveoli, leading to impaired gas exchange. It is a major component of chronic obstructive pulmonary disease (COPD) and is primarily associated with smoking and environmental pollutants. Here’s an overview of its epidemiology:

  • The Global Burden of Disease (GBD) Study estimates that COPD affects approximately 10–12% of the world’s population over 40 years of age.

Emphysema Epidemiology Segmentation

DelveInsight’s Emphysema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Emphysema historical patient pools and forecasted Emphysema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Emphysema Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Emphysema Prevalence

  • Age-Specific Emphysema Prevalence

  • Gender-Specific Emphysema Prevalence

  • Diagnosed and Treatable Cases of Emphysema

Visit for more @ Emphysema Epidemiological Insights

Emphysema Market Outlook

​The emphysema market is poised for significant growth from 2023 to 2032, driven by the rising prevalence of the disease and the introduction of innovative therapies.​

Key Emphysema Market Drivers

  • Increasing Prevalence: Factors such as aging populations and rising smoking rates contribute to a higher incidence of emphysema.​

  • Therapeutic Advancements: Ongoing research and development efforts are leading to the introduction of novel treatments, including regenerative therapies and advanced inhalation devices.​

  • Awareness and Diagnosis: Improved awareness and diagnostic techniques are facilitating earlier detection and intervention.

Emphysema Key Companies

  • Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, and others

For more information, visit Emphysema Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Emphysema Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Emphysema, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Emphysema epidemiology in the 7MM

  • Emphysema marketed and emerging therapies

  • Emphysema companies

  • Emphysema market drivers and barriers

Table of Contents:

1 Emphysema Market Key Comprehensive Insights

2 Emphysema Market Report Introduction

3 Competitive Intelligence Analysis for Emphysema

4 Emphysema Market Analysis Overview at a Glance

5 Executive Summary of Emphysema

6 Emphysema Epidemiology and Market Methodology

7 Emphysema Epidemiology and Patient Population

8 Emphysema Patient Journey

9 Emphysema Treatment Algorithm, Emphysema Current Treatment, and Medical Practices

10 Key Endpoints in Emphysema Clinical Trials

11 Emphysema Marketed Therapies

12 Emphysema Emerging Therapies

13 Emphysema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Emphysema

16 Emphysema Market Key Opinion Leaders Reviews

18 Emphysema Market Drivers

19 Emphysema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Emphysema Epidemiology 2032

DelveInsight’s “Emphysema – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Emphysema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Emphysema Pipeline 2024

“Emphysema Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Emphysema market. A detailed picture of the Emphysema pipeline landscape is provided, which includes the disease overview and Emphysema treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Emphysema Market Expected to rise, 2032 | Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, expected to drive market

Severe Asthma Market Expected to rise, 2034 | AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Boehringer Ingelheim

“Severe Asthma Market Expected to rise 2034, DelveInsight”
The Severe Asthma market growth is driven by factors like increase in the prevalence of Severe Asthma, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Severe Asthma market report also offers comprehensive insights into the Severe Asthma market size, share, Severe Asthma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Severe Asthma market size growth forward.

Some of the key highlights from the Severe Asthma Market Insights Report:

  • In September 2024, Kinaset Therapeutics announced two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of frevecitinib (KN-002), the company’s lead clinical candidate, for treating moderate to severe asthma and COPD patients.

  • In May 2024, GSK reported positive topline results from its SWIFT-1 and SWIFT-2 Phase III trials, which evaluated the efficacy and safety of depemokimab compared to a placebo in adults and adolescents with severe asthma associated with type 2 inflammation and elevated blood eosinophil counts.

  • In April 2024, Sanofi announced that 25 abstracts covering both approved and investigational treatments would be presented at the American Thoracic Society (ATS) International Conference. A key highlight includes the first Phase IIb data presentation on rilzabrutinib for moderate to severe asthma.

  • Several key pharmaceutical companies, including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others, are developing novel products to improve the Severe Asthma treatment outlook.

  • Severe asthma therapies are Cinqair (reslizumab), Fasenra (benralizumab), GSK3511294 (Depemokimab), PT010, and others.

  • The expansion of the severe asthma market is anticipated to be primarily driven by the increasing prevalence of the condition, advancements in diagnostic techniques, a surge in product launches, and growing pharmaceutical research efforts.

  • Asthma cases diagnosed by severity are categorized into two main groups: Intermittent and Persistent, with the latter further classified into mild, moderate, and severe forms. In 2023, intermittent asthma represented the highest number of cases, totaling approximately 25 million across the 7MM (Seven Major Markets).

  • Within the 7MM, the United States recorded the highest number of severe asthma cases, reaching around 2 million in 2023, followed by Japan with approximately 0.8 million cases.

  • Among the currently approved biologics for severe asthma treatment, Dupixent (dupilumab) is projected to achieve the largest market share by 2034 in the 7MM.

  • With the anticipated approval of new therapies between 2024 and 2034, the severe asthma treatment market is expected to witness significant growth, with a robust compound annual growth rate (CAGR) over the forecast period.

  • As per DelveInsight analysis, the Severe Asthma market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Severe Asthma Market Landscape

Severe Asthma Overview

Severe asthma is a significant challenge among respiratory diseases, marked by persistent and debilitating symptoms that persist despite standard treatments. Unlike milder forms, it often involves ongoing symptoms that greatly impact daily life and overall well-being. This complexity arises from multiple factors, including airway inflammation, structural changes (remodeling), and heightened responsiveness, leading to recurrent bronchial obstruction and airflow restriction. Additionally, the classification of severe asthma into type-2 and non-type-2 inflammation highlights its diverse nature, requiring personalized treatment strategies. While advancements in asthma management have been made, many individuals with severe asthma still struggle to achieve adequate control, emphasizing the critical need for targeted therapies to address this unmet medical challenge.

Do you know the treatment paradigms for different countries? Download our Severe Asthma Market Sample Report

Severe Asthma Epidemiology Insights

  • In 2023, approximately 26 million diagnosed cases of asthma were reported in the United States, encompassing both pediatric and adult populations.

  • Across the 7MM, the total number of diagnosed severe asthma cases reached 5.1 million, accounting for about 9% of all diagnosed asthma cases. Forecasts suggest a significant rise in these numbers by 2034.

Severe Asthma Epidemiology Segmentation

DelveInsight’s Severe Asthma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Severe Asthma historical patient pools and forecasted Severe Asthma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Severe Asthma Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Severe Asthma Prevalence

  • Age-Specific Severe Asthma Prevalence

  • Gender-Specific Severe Asthma Prevalence

  • Diagnosed and Treatable Cases of Severe Asthma

Visit for more @ Severe Asthma Epidemiological Insights

Severe Asthma Treatment Market

Severe asthma is characterized not only by difficult-to-control symptoms but also by significant abnormalities in pulmonary function. Accurate diagnosis is challenging due to the lack of precise physiological characterization, often relying on symptom assessment and treatment response.

Diagnosis typically involves confirming episodic airflow obstruction or airway hyperresponsiveness and assessing reversibility through spirometry. A key indicator is an increase in FEV1 (forced expiratory volume in one second) by >200 mL and 12% after inhaling a short-acting beta-agonist (SABA).

Treatment primarily focuses on reducing airway inflammation and preventing symptoms. Inhaled corticosteroids (ICS) are the cornerstone for persistent asthma, while SABAs provide quick relief during acute symptoms. If asthma remains uncontrolled, additional long-term controller medications such as long-acting beta-agonists (LABAs), montelukast, or theophylline may be introduced. Oral corticosteroids are considered for patients with persistent symptoms and flare-ups.

For severe cases, six approved monoclonal antibodies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab) serve as biologic add-on therapies. However, no approved treatments currently exist for severe non-eosinophilic asthma, which does not respond to corticosteroids.

Severe Asthma Market Outlook

The Severe Asthma market is evolving with a focus on reducing symptoms, minimizing side effects, and maintaining normal activity levels. Management strategies prioritize disease severity and the selection of appropriate therapies to control symptoms and prevent exacerbations.

For mild persistent asthma, low-dose inhaled corticosteroids (ICS) effectively reduce severe attacks and improve control. If symptoms persist, combining ICS with long-acting beta-agonists (LABA) is the preferred approach, along with short-acting beta-agonists (SABA) as needed. An alternative strategy involves using ICS/LABA as both maintenance and reliever therapy.

In severe cases, higher doses of inhalers and additional medications like anticholinergics help relax airway muscles. However, long-term reliance on combination inhaled therapies may be insufficient, and oral steroids pose risks due to potential side effects.

The market is experiencing growth with the development of novel therapies. Leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, Bond Avillion, Novartis, Roche, AB Science, and Theravance Biopharma, are actively investing in research and innovation to address unmet medical needs and enhance treatment outcomes for severe asthma patients.

Severe Asthma Marketed Therapies

  • Cinqair (reslizumab): Teva Pharmaceutical

  • Fasenra (benralizumab): AstraZeneca

Severe Asthma Emerging Therapies

  • GSK3511294 (Depemokimab): GlaxoSmithKline

  • PT010: AstraZeneca

Severe Asthma Key Companies

  • AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others

For more information, visit Severe Asthma Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Severe Asthma Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Severe Asthma, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Severe Asthma epidemiology in the 7MM

  • Severe Asthma marketed and emerging therapies

  • Severe Asthma companies

  • Severe Asthma market drivers and barriers

Table of Contents:

1 Severe Asthma Market Key Comprehensive Insights

2 Severe Asthma Market Report Introduction

3 Competitive Intelligence Analysis for Severe Asthma

4 Severe Asthma Market Analysis Overview at a Glance

5 Executive Summary of Severe Asthma

6 Severe Asthma Epidemiology and Market Methodology

7 Severe Asthma Epidemiology and Patient Population

8 Severe Asthma Patient Journey

9 Severe Asthma Treatment Algorithm, Severe Asthma Current Treatment, and Medical Practices

10 Key Endpoints in Severe Asthma Clinical Trials

11 Severe Asthma Marketed Therapies

12 Severe Asthma Emerging Therapies

13 Severe Asthma: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Severe Asthma

16 Severe Asthma Market Key Opinion Leaders Reviews

18 Severe Asthma Market Drivers

19 Severe Asthma Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Severe Asthma Epidemiology 2034

DelveInsight’s “Severe Asthma – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Severe Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Severe Asthma Pipeline 2024

“Severe Asthma Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Severe Asthma market. A detailed picture of the Severe Asthma pipeline landscape is provided, which includes the disease overview and Severe Asthma treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Severe Asthma Market Expected to rise, 2034 | AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Boehringer Ingelheim

Pleural Diseases Market Expected to rise, 2032 | Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences

“Pleural Diseases Market Expected to rise, DelveInsight”
The Pleural Diseases market growth is driven by factors like increase in the prevalence of Pleural Diseases, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Pleural Diseases market report also offers comprehensive insights into the Pleural Diseases market size, share, Pleural Diseases epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Pleural Diseases market size growth forward.

Some of the key highlights from the Pleural Diseases Market Insights Report:

  • Nivolumab and Ipilimumab Combination: In October 2020, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of adults with unresectable MPM. This approval was based on a clinical trial demonstrating a median overall survival of 18.1 months for patients receiving the combination therapy, compared to 14.1 months for those undergoing standard chemotherapy. ​

  • Pembrolizumab (Keytruda): In September 2024, the FDA approved pembrolizumab in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for unresectable advanced or metastatic MPM. This decision was supported by Phase 3 trial data indicating a 21% reduction in the risk of death compared to chemotherapy alone. ​

  • ACES™ Automatic Continuous Effusion Shunt System: In October 2023, the FDA granted 510(k) clearance for the ACES™ System, an innovative, fully implantable device designed to manage chronic pleural effusion without external catheters or frequent hospital visits. Clinical studies are underway to assess its efficacy and impact on patient quality of life.

  • Several key pharmaceutical companies, including Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences, and others, are developing novel products to improve the Pleural Diseases treatment outlook.

  • As per DelveInsight analysis, the Pleural Diseases market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Pleural Diseases Market Landscape

Pleural Diseases Overview

Pleural diseases affect the pleura, which is the thin, double-layered membrane surrounding the lungs and lining the chest cavity. These diseases can cause inflammation, fluid buildup, or structural issues that affect lung function and cause symptoms like chest pain and difficulty breathing.

Do you know the treatment paradigms for different countries? Download our Pleural Diseases Market Sample Report

Pleural Diseases Epidemiology Segmentation

DelveInsight’s Pleural Diseases market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Pleural Diseases historical patient pools and forecasted Pleural Diseases patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Pleural Diseases Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Pleural Diseases Prevalence

  • Age-Specific Pleural Diseases Prevalence

  • Gender-Specific Pleural Diseases Prevalence

  • Diagnosed and Treatable Cases of Pleural Diseases

Visit for more @ Pleural Diseases Epidemiological Insights

Pleural Diseases Market Outlook

​The global pleural diseases market is experiencing significant growth, driven by advancements in medical technology, increasing prevalence of respiratory disorders, and a focus on personalized medicine.

The pleural diseases market is poised for substantial growth, driven by technological advancements, increasing disease prevalence, and rising investments in healthcare infrastructure. The development of personalized medicine, targeted therapies, and minimally invasive procedures is expected to enhance patient outcomes and quality of life. ​

Pleural Diseases Key Companies

  • Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences, and others

For more information, visit Pleural Diseases Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Pleural Diseases Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Pleural Diseases, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Pleural Diseases epidemiology in the 7MM

  • Pleural Diseases marketed and emerging therapies

  • Pleural Diseases companies

  • Pleural Diseases market drivers and barriers

Table of Contents:

1 Pleural Diseases Market Key Comprehensive Insights

2 Pleural Diseases Market Report Introduction

3 Competitive Intelligence Analysis for Pleural Diseases

4 Pleural Diseases Market Analysis Overview at a Glance

5 Executive Summary of Pleural Diseases

6 Pleural Diseases Epidemiology and Market Methodology

7 Pleural Diseases Epidemiology and Patient Population

8 Pleural Diseases Patient Journey

9 Pleural Diseases Treatment Algorithm, Pleural Diseases Current Treatment, and Medical Practices

10 Key Endpoints in Pleural Diseases Clinical Trials

11 Pleural Diseases Marketed Therapies

12 Pleural Diseases Emerging Therapies

13 Pleural Diseases: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Pleural Diseases

16 Pleural Diseases Market Key Opinion Leaders Reviews

18 Pleural Diseases Market Drivers

19 Pleural Diseases Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Pleural Diseases Epidemiology 2032

DelveInsight’s “Pleural Diseases – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Pleural Diseases epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pleural Diseases Pipeline 2024

“Pleural Diseases Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pleural Diseases market. A detailed picture of the Pleural Diseases pipeline landscape is provided, which includes the disease overview and Pleural Diseases treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pleural Diseases Market Expected to rise, 2032 | Chiesi Farmaceutici, Faron Pharmaceuticals, Actelion Pharmaceuticals, Meril Life Sciences

Digitrix Media Unveils Immersia: A Revolutionary 3D Art Ecosystem for Galleries and Museums

Digitrix Media Unveils Immersia: A Revolutionary 3D Art Ecosystem for Galleries and Museums

Immersia leverages cutting-edge technology to convert a simple 2D image into a three-dimensional masterpiece
Media empowers galleries to thrive in the evolving digital landscape. Digitrix Media launches Immersia, a revolutionary Web2-to-Web3 art platform dubbed “The Artverse.” It transforms 2D artwork into immersive 3D digital twins with brushstrokes and lighting effects. Offering 3,000 customizable 3D galleries, VR access via Meta, and analytics, Immersia bridges physical and digital art. Beta-tested with 200 global artists, it redefines engagement for galleries and museums.

Hong Kong – Digitrix Media, a trailblazer in digital innovation, today announced the launch of Immersia, a groundbreaking Web2-to-Web3 native art platform designed to redefine how art is experienced, shared, and curated. Dubbed “The Artverse,” this ecosystem transforms traditional 2D artwork into immersive 3D digital twins, offering unparalleled opportunities for public and private galleries, museums, artists, and collectors worldwide.

Immersia leverages cutting-edge technology to convert a simple 2D image into a three-dimensional masterpiece. Using proprietary algorithms, the platform recreates visible brushstrokes, lighting effects, and perspective shifts, replicating the in-person viewing experience. This innovation marks a significant leap forward in bridging the physical and digital art worlds.

The platform offers a robust suite of tools tailored to the needs of the modern art ecosystem:

3D Galleries: With an initial capacity of 3,000 virtual galleries, users can craft customizable exhibition spaces in minutes. Supporting paintings, photographs, videos, and more, these galleries are accessible on mobile devices, web browsers, or in virtual reality through partnerships with Meta. Immersive Features: Art enthusiasts can zoom, tilt, and pan artworks in 3D, while galleries can host live events, video-enhanced exhibitions, and podcasts to deepen engagement. Analytics and Insights: Artists and curators gain access to detailed dashboards, enabling them to track performance, analyze audience preferences, and refine their strategies.

Designed with accessibility in mind, Immersia’s intuitive interface removes the technical hurdles often linked to Web3 adoption, making it approachable for creators of all skill levels. During its beta phase, Digitrix Media partnered with 200 international artists, collectors, and universities, incorporating real-world feedback to perfect the platform’s features.

Immersia is poised to transform how galleries and museums—both public and private—engage with their audiences. From virtual exhibitions to data-driven insights, the platform offers a scalable solution for institutions seeking to modernize their offerings while preserving the essence of art.

About Digitrix Media

Digitrix Media is a forward-thinking technology company dedicated to pushing the boundaries of digital experiences. With a focus on innovative solutions, Digitrix Media empowers galleries to thrive in the evolving digital landscape.

Media Contact
Company Name: Digitrix Media
Contact Person: Jasper Kit
Email: Send Email
Country: HongKong
Website: https://www.digitrixtech.com/

Historic Hong Kong Exhibition Showcases Filipino Artistic Talent Across Borders

Historic Hong Kong Exhibition Showcases Filipino Artistic Talent Across Borders

Poster of “Unity in Diversity: Filipino Artists Across Borders,” exhibition at the Hong Kong Visual Arts Centre
A vibrant celebration of Filipino creativity unfolds in Hong Kong with the exhibition “Unity in Diversity: Filipino Artists Across Borders,” showcasing over 70 master works from artists in Hong Kong, the Philippines, New York, and the UK. Running from February 26 to March 3, 2025, it highlights diverse artistic expressions, inviting reflection on identity and cultural heritage. Curated by Hong Kong-based artists Rodolfo Canete Jr. and Abigail Camaya-Hills

HONG KONG – A vibrant celebration of Filipino creativity is captivating audiences in Hong Kong, where the community of Filipinos in the city is finding inspiration in the works of their compatriots. An art exhibition titled “Unity in Diversity: Filipino Artists Across Borders” opened this week, featuring more than 70 masterpieces crafted by Filipino artists from Hong Kong, the Philippines, New York, and the United Kingdom. This is probably the single biggest overseas exhibition of contemporary Filipino artists ever.

The exhibition, held at the Hong Kong Visual Arts Center from February 26 to March 3, showcases an array of artistic expressions, including intricate sculptures, vivid paintings, woven textiles, and other stunning creations. Consul General of the Philippines in Hong Kong, Germinia Aguilar-Usudan, hailed the event as a testament to the ingenuity and spirit of Filipino artists, whose works are resonating not only with the Filipino diaspora but also with a broader international audience.

Among the exhibition’s standout participants is Ferdinand Cacnio, the guest of honor, whose presence elevates the opening festivities. Renowned for his mastery in sculpting, Cacnio unveils a stunning collection of brass sculptures that meld fluidity with precision. For the first time in Hong Kong, he also presents his paintings, offering a rare glimpse into the versatility of this celebrated artist. His works serve as a bridge between tradition and innovation, setting the tone for an exhibition that promises to push artistic boundaries.

Joining Cacnio is Norman Dreo, a painter par excellence whose meticulous attention to detail pays homage to the Old Masters. Dreo’s two paintings are a labor of love, each stroke echoing the timeless techniques of classical artistry while infusing them with a contemporary Filipino spirit. His works invite viewers to linger, uncovering layers of meaning in their intricate compositions.

The exhibition also celebrates the evocative power of abstract expression through Lydia Velasco’s striking Filipino female figures. Velasco’s bold forms capture the essence of womanhood, blending strength and grace in a dance of shapes and shadows. Equally compelling is Richard Dela Cruz’s storytelling, where Rococo-inspired engravings come alive with narrative depth, drawing viewers into a world of ornate elegance and hidden tales.

Innovation takes center stage with Boholana artist Nicole Asares, whose outline-embossed paintings defy conventional boundaries. Her creations leap across the canvas, intertwining form and imagination in a mesmerizing dance that challenges the viewer’s perception. Similarly, Jeff Dahilan’s meticulous triangular mosaics offer a geometric symphony of color and texture, each piece a testament to patience and precision. Meanwhile, “rockstar” painter Kenneth John Montegrande enchants with his sublime blue-toned landscape, where serene hues evoke a meditative stillness that resonates deeply.

A significant highlight of this exhibition is the debut of Kareem Moumina, a prolific Filipino-Arab-American artist based in New York. Marking his first appearance in a Filipino art exhibition, Moumina’s huge oil painting commands attention with its fusion of tropical settings and dreamlike elements influenced by visits to the native land of his Filipino mother. His work explores the beauty of diversity—an interplay of cultures and visions that mirrors the exhibition’s overarching theme. Through his bold brushstrokes and vibrant palette, Moumina invites viewers to reflect on the interconnectedness of identity and environment, making his contribution a fitting crescendo to this artistic celebration.

This landmark exhibition not only showcases the brilliance of individual artists but also underscores the collective strength of Filipino creativity on the global stage. From Cacnio’s sculptural innovations to Moumina’s cross-cultural narratives, each contributor weaves a thread into a larger story—one of heritage, imagination, and resilience. For a full list of participating artists, click here, and prepare to be inspired by a display that transcends borders and redefines artistic possibility.

“These works are more than just art; they’re a bridge connecting Filipinos across the world and showcasing our talent to others,” Aguilar-Usudan said during the opening ceremony. Visitors from various backgrounds have expressed awe at the skill and creativity on display, with many noting the universal appeal of the pieces.

The event underscores Hong Kong’s role as a cultural hub for the Filipino community, which forms one of the city’s largest expatriate groups. For the artists, it’s an opportunity to share their heritage and stories through a kaleidoscope of mediums, proving that creativity knows no borders.

The exhibition is jointly curated by Hong Kong-based artists Rodolfo Canete Jr. and Abigail Camaya Hills of Galleria Camaya.

As the exhibition continues through the week, it promises to leave a lasting impression on all who witness the remarkable talent of Filipino artists thriving across the globe.

Media Contact
Company Name: Galleria Camaya
Contact Person: Gail Hills
Email: Send Email
Country: HongKong
Website: https://galleriacamaya.art